Back to Search
Start Over
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.
- Source :
-
Frontiers in immunology [Front Immunol] 2020 Oct 15; Vol. 11, pp. 584241. Date of Electronic Publication: 2020 Oct 15 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Background: Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPLs) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-β <subscript>2</subscript> GPI), and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-β <subscript>2</subscript> GPI antibodies was not reported.<br />Objective: To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-β <subscript>2</subscript> GPI antibodies.<br />Methods: ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events.<br />Results: Anti-β <subscript>2</subscript> GPI IgG/IgA/IgM was the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM was detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of β <subscript>2</subscript> GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-β <subscript>2</subscript> GPI nor with thrombosis.<br />Conclusions: aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β <subscript>2</subscript> GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.<br /> (Copyright © 2020 Borghi, Beltagy, Garrafa, Curreli, Cecchini, Bodio, Grossi, Blengino, Tincani, Franceschini, Andreoli, Lazzaroni, Piantoni, Masneri, Crisafulli, Brugnoni, Muiesan, Salvetti, Parati, Torresani, Mahler, Heilbron, Pregnolato, Pengo, Tedesco, Pozzi and Meroni.)
- Subjects :
- Aged
Aged, 80 and over
Antibodies, Anticardiolipin blood
Antiphospholipid Syndrome blood
COVID-19 blood
COVID-19 virology
Critical Illness
Enzyme-Linked Immunosorbent Assay
Epitopes immunology
Female
Humans
Immunoglobulin A blood
Immunoglobulin A immunology
Immunoglobulin G blood
Immunoglobulin G immunology
Immunoglobulin M blood
Immunoglobulin M immunology
Luminescent Measurements
Male
Middle Aged
Phosphatidylserines immunology
Prothrombin immunology
Thrombosis immunology
beta 2-Glycoprotein I immunology
Antibodies, Anticardiolipin immunology
Antiphospholipid Syndrome immunology
COVID-19 immunology
SARS-CoV-2
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 33178218
- Full Text :
- https://doi.org/10.3389/fimmu.2020.584241